Lung colonization with Enterobacteriaceae producing extended-spectrum β-lactamases in cystic fibrosis patients

Pediatric Pulmonology

Volumn 24, Issue 3, 1997, Pages 213-217

  Cantón, Rafael ^a   Morosini, María Isabel ^a   Ballestero, Salomé ^a   Alvarez, María Elena ^a   Escobar, Héctor ^a   Máiz, Luis ^a   Baquero, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CLAVULANIC ACID; COLISTIN; IMIPENEM; TOBRAMYCIN;

ADOLESCENT; AEROSOL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; CASE REPORT; COLONY FORMING UNIT; CYSTIC FIBROSIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALMONELLA ENTERICA;

ADOLESCENT; AZTREONAM; BETA-LACTAMASES; CEFTAZIDIME; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; SPUTUM;

EID: 0030930792     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199709)24:3<213::AID-PPUL7>3.0.CO;2-N     Document Type: Article

References (28)

1. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991; 4:35-51.
2. Hoiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr Scand. 1982; 301(Suppl C):33-54.
3. Ojeda-Vargas M, Pacheco A, Elia M, Villaverde R, Baquero F. Proteus mirabilis as a cause of recurrent lung infections in a cystic fibrosis patient. Eur J Clin Microbiol Infect Dis. 1990; 9:234-235.
4. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother. 1991; 35:1697-1704.
5. Jacoby GA. Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994; 13(Suppl. 1):2-11.
6. Quinn JP. Clinical significance of extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis. 1994; 13(Suppl 1): 39-42.
7. Morosini MI, Cantón R, Martínez-Beltrán J, Negri MC, Pérez-Díaz JC, Baquero F, Blázquez J. New extended-spectrum TEM-type β-lactamase from Salmonella enterica subsp. enterica isolated in a nosocomial outbreak. Antimicrob Agents Chemother. 1995; 39:458-461.
8. Wong K, Roberts MC, Owens L, Fife M, Smith AL. Selective media for the quantification of bacteria in cystic fibrosis sputum. J Med Microbiol. 1984; 17:113-119.
9. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A3. Villanova, PA: NCCLS, 1993.
10. Miller JH. Experiments in Molecular Genetics. Cold Spring Harbor, Cold Spring Harbor Laboratory, New York: 1972.
11. Matthew M, Harris AM, Marshall H, Ross GW. The use of analytical isoelectric focusing for detection and identification of β-lactamases. J Gene Microbiol. 1975; 88:169-178.
12. Papanicolaou GA, Medeiros AA. Discrimination of extended spectrum β-lactamases by a novel nitrocefin competition assay. Antimicrob Agents Chemother. 1990; 34:2184-2192.
13. Chanal CM, Sirot DL, Petit A, Labia R, Morand A, Sirot JL, Cluzel RA. Multiplicity of TEM-derived β-lactamases from K. pneumoniae strains isolated at the same hospital and relationship between the responsible plasmids. Antimicrob Agents Chemother. 1989; 33:1951-1920.
14. Gutmann L, Ferré B, Goldstein FW, Rizk N, Pinto-Schuster E, Acar JF, Collatz E. SHV-5, a novel SHV-type β-lactamase that hydrolyses broad-spectrum cephalosporins and monobactams. Antimicrob Agents Chemother. 1989; 33:951-956.
15. Ballestero S, Escobar H, Villaverde R, Elia M, Ojeda-Vargas M, Baquero F. Continuous monitoring of antimicrobial resistance in cystic fibrosis patients. In: Escobar H, Baquero F, Suarez L, eds. Clinical Ecology of Cystic Fibrosis. Amsterdam: Excerpta Medica, Elsevier Science Publisher, 1993:63-72.
16. Pedersen SS, Pressler T, Hoiby N, Bentjon MW, Koch C. Imipenem/cilastatin treatment of multiresistant Ps. aeruginosa lung infections in cystic fibrosis. J Antimicrob Chemother. 1985; 16: 626-635.
17. Alvarez M, Alvarez ME, Cantón R, Maiz L, Baquero F. Comparative penicillin, cefotaxime and erythromycin susceptibility profile of oropharyngeal viridans group streptococci isolates obtained from cystic fibrosis and non-cystic fibrosis patients. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. 1996:88. Abstract E41.
18. Ballestero S, Escobar H, Villaverde R, Elia M, Ojeda-Vargas M, Baquero F. Microbiological parameters and clinical evolution in cystic fibrosis patients. In: Escobar H, Baquero F, Suarez L, eds. Clinical Ecology of Cystic Fibrosis. Amsterdam: Excerpta Medica, Elsevier Science Publisher, 1993:55-62.
19. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987; 81:272-279.
20. Ramsey B. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996; 335:179-188.
21. Carrasco S, Baquero F. The general approach to cystic fibrosis pulmonary infection in Spain. In: Bauernfeind A, Marks MI, Strandvik B, eds. Cystic Fibrosis Pulmonary Infections: Lessons From Around the World. Basel: Birkhäuser Verlag, 1996:223-228.
22. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum β-lactamase. J Antimicrob Chemother. 1996; 37:203-204.
23. Sanders CC. Cefepime: The next generation? Clin Infect Dis. 1993; 17:369-379.
24. Arguedas AG, Stutman HR, Zaleska M, Knupp, CA, Marks MI, Nussbuum E. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child. 1992; 146:797-802.
25. Casellas JM, Bauernfeind A, Goldberg M, Cuba J, Merino S, Gilardoni M, San Juan J. Fallo terapéutico en una bacteriemia por Klebsiella pneumoniae tratada con cefepima y amikacina. Rev Esp Quimioterap. 1995; 8:327-328.
26. Labia R, Morad A, Tiwari K, Sirot D, Channal C. Interactions of meropenem with β-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother. 1989; 24(Suppl A):219-223.
27. Fernández-Rodríguez A, Cantón R, Pérez-Díaz JC, Martínez-Beltrán J, Picazo JJ, Baquero F. Aminoglycoside-modifying enzymes in clinical isolates harboring extended-spectrum β-lactamases. Antimicrob Agents Chemother. 1992; 36:2536-2538.
28. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40:2488-2493.